Markets:

Overview

News

Currencies

International

Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

127.48 +4.01 (+3.25%)

Streaming Delayed Price Updated: 1:49 PM EDT, Aug 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

29 30 Next >

Incyte Reports First Quarter 2026 Financial Results and Provides Business Updates

April 28, 2026

From Incyte

Via Business Wire

Incyte Appoints Suketu (Suky) Upadhyay as Chief Financial Officer

April 28, 2026

From Incyte

Via Business Wire

Incyte Earnings: What To Look For From INCY

April 26, 2026

Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting results this Tuesday before the bell. Here’s what to look for. Incyte beat analy...

Via StockStory

Topics Artificial Intelligence

Incyte (INCY) Q4 2024 Earnings Transcript ↗

April 22, 2026

Incyte (INCY) Q4 2024 Earnings Transcript

Via The Motley Fool

Incyte Corp. (NASDAQ:INCY) Presents a Compelling Value Investment Case ↗

April 20, 2026

Via Chartmill

Incyte Corp (NASDAQ:INCY) Presents a Compelling Value Case with Strong Fundamentals ↗

February 21, 2026

Via Chartmill

Incyte Highlights New Phase 3 Tafasitamab Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

April 21, 2026

From Incyte

Via Business Wire

INCYTE CORP (NASDAQ:INCY) Presents a High-Growth Momentum Breakout Setup ↗

April 11, 2026

Incyte Corp (INCY) shows strong earnings growth and a positive technical setup, suggesting a potential breakout for momentum investors.

Via Chartmill

Incyte to Report First Quarter Financial Results

April 09, 2026

From Incyte

Via Business Wire

Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales

April 07, 2026

From Palvella Therapeutics Inc.

Via GlobeNewswire

Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)

April 02, 2026

From Adagene Inc.

Via GlobeNewswire

A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack

March 29, 2026

Looking back on biotechnology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Incyte (NASDAQ:INCY) and its peers. The bio...

Via StockStory

Topics Artificial Intelligence

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting

March 28, 2026

From Incyte

Via Business Wire

Incyte Announces Executive Leadership Appointments

March 25, 2026

From Incyte

Via Business Wire

2 Growth Stocks with Explosive Upside and 1 We Avoid

March 23, 2026

Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market va...

Via StockStory

Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting

March 20, 2026

From Incyte

Via Business Wire

1 Cash-Heavy Stock to Target This Week and 2 Facing Headwinds

March 16, 2026

Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they strugg...

Via StockStory

2 Value Stocks to Consider Right Now and 1 We Ignore

March 13, 2026

Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built the...

Via StockStory

Incyte (INCY): Buy, Sell, or Hold Post Q4 Earnings?

March 11, 2026

Over the past six months, Incyte has been a great trade, beating the S&P 500 by 8.1%. Its stock price has climbed to $95.88, representing a healthy 11.3% inc...

Via StockStory

Topics Stocks

Incyte’s Drug Approved In Europe For Treating Yet Another Rare Cancer ↗

March 06, 2026

The company said that EC approved Zynyz in combination with carboplatin and paclitaxel for adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal...

Via Stocktwits

Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)

March 06, 2026

From Incyte

Via Business Wire

1 Cash-Producing Stock with Exciting Potential and 2 We Avoid

March 04, 2026

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...

Via StockStory

3 S&P 500 Stocks to Target This Week

February 23, 2026

The S&P 500 (^GSPC) is full of established businesses, but only some continue to outperform the market. A few standout companies are thriving thanks to strong fundamentals and sustained competitive...

Via StockStory

Topics Stocks

Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year ↗

February 23, 2026

Praxis Precision Medicines develops therapies for neurological and psychiatric disorders, aiming to address unmet needs in the CNS market.

Via The Motley Fool

Topics Regulatory Compliance

This Fund Bet Nearly $40 Million on GRAIL Last Quarter. The Stock Just Plunged Over 50% ↗

February 23, 2026

GRAIL develops advanced cancer detection technologies, serving healthcare providers and individuals seeking early diagnostic solutions.

Via The Motley Fool

Topics Regulatory Compliance

February 18, 2026

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps...

Via StockStory

Registration Momentum Builds Across the Oncology Pipeline

February 17, 2026

Issued on behalf of Oncolytics Biotech Inc.

From USA News Group

Via GlobeNewswire

Incyte to Present at Upcoming Investor Conferences

February 17, 2026

From Incyte

Via Business Wire

The Top 5 Analyst Questions From Incyte’s Q4 Earnings Call

February 17, 2026

Incyte’s fourth quarter was met with a negative market reaction, despite the company delivering revenue growth above Wall Street expectations. Management attributed this performance to strong...

Via StockStory

Topics Earnings

Incyte (INCY) Deep Dive: Navigating the 2026 Crossroads Following Earnings Miss

February 11, 2026

As of February 11, 2026, Incyte Corporation (NASDAQ: INCY) finds itself at a pivotal crossroads. Known for over a decade as a one-drug powerhouse centered on the hematology blockbuster Jakafi, the...

Via Finterra

Topics Economy Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

29 30 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.